Shopping Cart 0
Cart Subtotal
USD 0

Sierra Oncology Inc (SRRA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 750
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Summary

Sierra Oncology Inc (Sierra Oncology), formerly ProNAi Therapeutics Inc is a clinical stage drug development company that develops and commercializes DNA damage response therapeutics for the treatment of cancer. The company's product candidate includes SRA737, an orally bioavailable small molecule inhibitor of Checkpoint kinase 1. It also develops SRA141, a small molecule inhibitor of the cell division cycle 7 kinase. Sierra Oncology offers DNA damage response services such as cellular pathways, monitoring, signalling, and repairing DNA damage. The company also provides registration and commercialization of product candidates. It operates in the US and Canada. Sierra Oncology is headquartered in Vancouver, British Columbia, Canada.

Sierra Oncology Inc (SRRA)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Sierra Oncology Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Sierra Oncology Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Sierra Oncology Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Sierra Oncology Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Sierra Oncology Inc, Medical Devices Deals, 2012 to YTD 2018 9

Sierra Oncology Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Sierra Oncology Inc, Pharmaceuticals & Healthcare, Deal Details 11

Asset Purchase 11

Sierra Oncology Acquires Momelotinib and Activin Receptor from Gilead Sciences 11

Venture Financing 13

ProNAi Therapeutics Raises USD1.3 Million in Venture Financing 13

ProNAi Therapeutics Raises USD 59.5 Million In Series D Financing 14

ProNAi Therapeutics Raises USD 12 Million In Series C Financing 16

ProNAi Therapeutics Raises USD 11 Million In Venture Financing 17

ProNAi Therapeutics Raises USD 4.3 Million In Venture Financing 18

ProNAi Therapeutics Raises USD0.3 Million in Venture Financing 19

Licensing Agreements 20

ProNAi Therapeutics Enters into Licensing Agreement with CRT Pioneer 20

ProNAi Therapeutics Enters into Licensing Agreement with Carna Biosciences 21

Marina Biotech Enters Into Licensing Agreement With ProNAi Therapeutics For DNAi Therapeutics 22

Equity Offering 23

Sierra Oncology Plans to Raise up to USD200 Million in Public Offering of Securities 23

Sierra Oncology Prices Public Offering of Shares for USD42.8 Million 24

Sierra Oncology Completes Public Offering of Shares for USD29.5 Million 26

ProNAi Therapeutics Raises USD158.4 Million in IPO 28

Sierra Oncology Inc-Key Competitors 30

Sierra Oncology Inc-Key Employees 31

Sierra Oncology Inc-Locations And Subsidiaries 32

Head Office 32

Other Locations & Subsidiaries 32

Recent Developments 33

Financial Announcements 33

Aug 09, 2018: Sierra Oncology Reports Second Quarter Results 33

May 10, 2018: Sierra Oncology Reports First Quarter Results 35

Feb 27, 2018: Sierra Oncology Reports 2017 Year End Results 36

Nov 08, 2017: Sierra Oncology Reports Third Quarter Results 38

Aug 10, 2017: Sierra Oncology Reports Second Quarter 2017 Results 40

May 09, 2017: Sierra Oncology Reports First Quarter 2017 Results 42

Mar 02, 2017: Sierra Oncology Reports 2016 Year-End Results 43

Product News 45

02/27/2018: Sierra Oncology Provides Update on SRA141 45

02/06/2018: Sierra Oncology to host program update on SRA141 on February 27th in New York 46

Other Significant Developments 47

Jan 09, 2017: ProNAi Relaunched as Sierra Oncology to Advance DDR-Based Cancer Drugs 47

Appendix 48

Methodology 48

About GlobalData 48

Contact Us 48

Disclaimer 48


List Of Figure

List of Figures

Sierra Oncology Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Sierra Oncology Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Sierra Oncology Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Sierra Oncology Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Sierra Oncology Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Sierra Oncology Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

Sierra Oncology Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Sierra Oncology Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Sierra Oncology Inc, Medical Devices Deals, 2012 to YTD 2018 9


List Of Table

List of Tables

Sierra Oncology Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Sierra Oncology Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Sierra Oncology Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Sierra Oncology Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Sierra Oncology Inc, Deals By Therapy Area, 2012 to YTD 2018 8

Sierra Oncology Inc, Medical Devices Deals, 2012 to YTD 2018 9

Sierra Oncology Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Sierra Oncology Acquires Momelotinib and Activin Receptor from Gilead Sciences 11

ProNAi Therapeutics Raises USD1.3 Million in Venture Financing 13

ProNAi Therapeutics Raises USD 59.5 Million In Series D Financing 14

ProNAi Therapeutics Raises USD 12 Million In Series C Financing 16

ProNAi Therapeutics Raises USD 11 Million In Venture Financing 17

ProNAi Therapeutics Raises USD 4.3 Million In Venture Financing 18

ProNAi Therapeutics Raises USD0.3 Million in Venture Financing 19

ProNAi Therapeutics Enters into Licensing Agreement with CRT Pioneer 20

ProNAi Therapeutics Enters into Licensing Agreement with Carna Biosciences 21

Marina Biotech Enters Into Licensing Agreement With ProNAi Therapeutics For DNAi Therapeutics 22

Sierra Oncology Plans to Raise up to USD200 Million in Public Offering of Securities 23

Sierra Oncology Prices Public Offering of Shares for USD42.8 Million 24

Sierra Oncology Completes Public Offering of Shares for USD29.5 Million 26

ProNAi Therapeutics Raises USD158.4 Million in IPO 28

Sierra Oncology Inc, Key Competitors 30

Sierra Oncology Inc, Key Employees 31

Sierra Oncology Inc, Subsidiaries 32

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Sierra Oncology Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.